Novel Body Composition Model Predicts Gastric Cancer Response to PD-1 Immunotherapy

A groundbreaking study has identified a novel clinical prediction model that could revolutionize treatment selection for gastric cancer (搜索)搜索该疾病 patients receiving immunotherapy. Researchers from Ruijin Hospital查看公司主页 and the First Affiliated Hospital of Zhengzhou University (搜索)搜索该词条 developed and validated a multivariate model combining body composition parameters with clinical factors to predict response to PD-1 antibody (搜索)搜索该药品-based therapy.

Addressing Critical Treatment Selection Challenges

Gastric cancer (搜索)搜索该疾病 remains one of the most malignant diseases worldwide, with over 40% of new cases occurring in China and approximately 80% of Chinese patients diagnosed at advanced stages. While PD-1 (搜索)搜索该靶点 antibodies combined with chemotherapy (搜索)搜索该药品 have shown promise as first-line treatment for HER2-negative advanced gastric cancer, existing biomarkers like PD-L1 (搜索)搜索该靶点 expression and microsatellite instability have significant limitations.

"The prevalence of PD-L1 (搜索)搜索该靶点 CPS ≥5 is approximately 10-30% in gastric cancer (搜索)搜索该疾病, and its expression can be affected by antibody type, staining procedures, and pathologist assessment," the researchers noted. "For most patients who do not have these biomarkers, whether they can benefit from therapy is still under investigation."

Novel Body Composition-Based Approach

The study analyzed 202 eligible patients in the training set, including 120 patients treated with chemotherapy (搜索)搜索该药品 plus PD-1 antibody (搜索)搜索该药品 and 82 patients treated with chemotherapy alone as reference. An external validation set of 43 patients was also included.

Using CT scans at the third lumbar vertebral level, researchers measured body composition parameters including skeletal muscle radiation attenuation (SMRA), which reflects muscle quality and fat infiltration. The analysis revealed three key predictive factors for tumor regression grade (TRG0/1):

• SMRA (OR = 0.950, 95% CI 0.908-0.994, p = 0.026)
• Weight loss ≥5% (OR = 2.296, 95% CI 1.038-5.087, p = 0.040)
• Neutrophil-to-lymphocyte ratio (NLR) (OR = 1.541, 95% CI 1.163-2.042, p = 0.003)

Superior Predictive Performance

The researchers developed a logistic regression model: Logit(p) = 1.407 − 0.055 × SMRA + 0.397 × NLR + 0.749 × weight loss. The model demonstrated superior predictive accuracy with an area under the ROC curve of 0.728 (p < 0.001), significantly outperforming individual parameters.

Using an optimal cutoff of 0.095, the model successfully stratified patients into good and poor response groups. In the immunotherapy cohort, 67.3% of patients classified as good responders achieved TRG0/1, compared to only 27.7% of poor responders (p < 0.001). Importantly, this stratification showed no significant difference in the chemotherapy (搜索)搜索该药品-alone cohort, confirming the model's specificity for immunotherapy response.

Clinical Impact and Survival Benefits

Patients stratified as good responders demonstrated significantly better overall survival compared to poor responders in the immunotherapy cohort (p = 0.001). The external validation cohort confirmed these findings, with 77.8% of good responders achieving TRG0/1 versus 36.0% of poor responders (p = 0.012).

The five-year overall survival rates were 66.0% in the immunotherapy cohort compared to 52.5% in the chemotherapy (搜索)搜索该药品-alone cohort, highlighting the potential benefits of optimal patient selection.

Biological Mechanisms and Clinical Implications

The study provides insights into the biological basis for these associations. Low SMRA (myosteatosis) is characterized by pathological fat accumulation in skeletal muscle related to cancer-induced systemic inflammation. "Elevated inflammatory factors associated with myosteatosis can significantly impair the host's antitumor immune response," the researchers explained.

The combination of SMRA, NLR, and weight loss reflects comprehensive information about patients' immune phenotypes, including skeletal muscle wasting, involuntary weight loss, and systemic inflammation—all features of cancer-associated cachexia that may influence immunotherapy response.

Practical Clinical Tool

Unlike complex molecular tests, this prediction model utilizes readily available clinical parameters from routine CT scans and laboratory tests, making it highly practical for clinical implementation. "This study provides a simple and efficient tool for clinicians to quickly obtain crucial information, allowing patients to receive timely treatment without waiting for complex, expensive, and time-consuming molecular tests," the authors noted.

The model's accessibility could be particularly valuable in resource-limited settings where advanced molecular testing may not be readily available, potentially democratizing precision oncology approaches for gastric cancer (搜索)搜索该疾病 patients worldwide.

Future Directions

The researchers acknowledge limitations including the retrospective single-center design and variable chemotherapy (搜索)搜索该药品 regimens, though all regimens were guideline-recommended. They plan to conduct prospective trials to further validate the model's predictive value and explore underlying molecular mechanisms.

This body composition-based prediction model represents a significant advancement in gastric cancer (搜索)搜索该疾病 immunotherapy, offering clinicians a practical tool to optimize treatment selection and improve patient outcomes through precision medicine approaches.